Interim report for Jan- Mar 2021 (Q1)
April 28 2021 at 8:30
|Interim report for Apr - June 2021 (Q2)||
July 22 2021 at 8:30
|Interim report for July - Sept 2021 (Q3)||
October 28 2021 at 8:30
Ticker symbol: MNTC
ISIN-kod: ISIN SE0012673291
Marketplace: Nasdaq First North Premier Stockholm
Certified Adviser: FNCA Sweden AB, phone 08-528 00 399.
Nasdaq First North Premier Stockholm is an alternative market operated by the different exchanges that make up the Nasdaq group. It does not have the same legal status as a regulated market. A company traded on Nasdaq First North premier Stockholm is subject to the same Market Abuse Regulation as the companies on the main market Nasdaq Stockholm. But, the issuer rulebook on First North Premier Stockholm is lighter than Nasdaq Stockholm and adjusted for growth companies. The risk of an investment in a company traded on First North Premier Stockholm may be higher than an investment in a company admitted to trading on a regulated market. All companies on First North have a Certified Adviser that monitors compliance with the rules.
Sustainable, social, and environmental issues are a core part of Mentice’s code of conduct and operations. Mentice’s business rationale is to contribute to reduced deaths, injuries, and social and economic costs resulting from medical errors and inefficiencies in the healthcare sector.
Mentice has a strong focus on continuous innovation of the products offered to optimize the quality of the solutions available to customers in hospitals, clinics, universities, research groups, and the medical technology industry.
Mentice has clear ambitions and principles for taking economic, social, and environmental responsibility.
Mentice promotes honesty, fairness, respect, integrity, trust and strives for a better way to behave toward each other and fellow citizens as well as to conserve and protect the environment. These qualities are not solely valuable to individuals: they are fundamental to corporate governance.
Mentice strives to excel and lead in the context of a healthy global business environment.
Here you can find all media articles, interviews and presentations with Mentice.
May 27, 2020
At the Annual General Meeting for 2018 held on 17 April 2019, it was resolved to adopt instructions and rules of procedure for the nomination committee according to which the nomination committee shall consist of the chairman of the board of directors and three ordinary members representing the three largest shareholders per the end of the third quarter each year.
Shareholders who wish to have a specific matter brought before the general meeting must submit a written request to the Company’s board of directors. Such request must normally have been received by the board of directors no later than seven weeks before the general meeting.
At the Annual General Meeting held on May 27, 2020, KPMG AB was elected as the Company’s auditor with Fredrik Waern as the principally responsible auditor.
Name of the company is Mentice AB. The company is a public company (publ).
The Head Office of the company shall be situated in Gothenburg.
The Company shall develop, market and sell products and services within medical simulation and other activities related thereto.
The Share Capital shall in total not be less than SEK 500,000 and not more than SEK 2,000,000.
The number of shares shall not be less than 20,000,000 and not more than 80,000,000.
The Board of Directors shall consist of three to ten members without any deputy members.
The company shall have one or two auditors with or without deputy auditors.
Notice of shareholders’ meetings shall be given by announcement in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) and by keeping the notice available at the Company’s website. Announcement that notice has been given shall be made in Dagens Industri.
Annual General Meetings shall be held annually within six months after the expiration of the financial year. At the Annual General Meeting the following matters shall be considered:
The financial year of the company shall be calendar year.
The company’s shares shall be registered in a CSD register pursuant to the Swedish Central Securities Depositories and Financial Instruments Accounts Act (SFS 1998:1479).
Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2022
Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with a focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2022 has been appointed.
At the Annual General Meeting held on 6th of May 2021, it was resolved to adopt instructions and rules of procedure for the nomination committee to which the nomination committee shall consist of the chairman of the board of directors and three ordinary members representing the three largest shareholders by 30th of September
The following members have been appointed to Mentice nomination committee for the 2022 Annual General Meeting:
Lawrence D Howell, appointed by Karin Howell,
Sophie Hagströmer, appointed by Bure Equity
Anna Sundberg, appointed by Handelsbanken Fonder
Lawrence D Howell, Chairman of the Board
Gösta Johannesson co-opted of the nomination committee is convening the first meeting.
The nomination committee represents approximately 56% of the total number of shares and votes.
The Nomination Committee shall prepare and present proposals for resolution by the Annual General Meeting regarding:
The Annual General Meeting will take place in Gothenburg on April 27th, 2022. Shareholders who have proposals for the Annual General Meeting are asked to submit these to the nomination committee by email to firstname.lastname@example.org, or by letter to: Mentice AB (publ), The Nomination Committee, Odinsgatan 10, 411 03 Gothenburg. In order for the nomination committee to process the received proposals with sufficient care, proposals must be submitted no later than March 18, 2022.